$SCWO
374Water Inc

2023 Q2 Form 10-Q Financial Statement

#000165495423005904 Filed on May 08, 2023

View on sec.gov

Income Statement

Concept 2023 Q2 2023 Q1 2022 Q1
Revenue $49.86K $801.5K $273.2K
YoY Change -95.16% 193.33%
Cost Of Revenue $45.26K $720.1K $248.0K
YoY Change -94.99% 190.4%
Gross Profit $4.606K $81.31K $25.25K
YoY Change -96.4% 222.09%
Gross Profit Margin 9.24% 10.15% 9.24%
Selling, General & Admin $1.502M $1.404M $713.3K
YoY Change 63.2% 96.83% 1683.25%
% of Gross Profit 32603.99% 1726.67% 2825.51%
Research & Development $272.0K $355.9K $185.7K
YoY Change -35.66% 91.7% 536.12%
% of Gross Profit 5904.56% 437.7% 735.41%
Depreciation & Amortization $15.17K $9.525K $235.00
YoY Change -9.22% 3953.19%
% of Gross Profit 329.35% 11.71% 0.93%
Operating Expenses $1.774M $1.760M $899.0K
YoY Change 32.08% 95.77% 1250.77%
Operating Profit -$1.769M -$1.679M -$873.7K
YoY Change 45.62% 92.12% 1212.84%
Interest Expense $74.97K $37.86K $840.00
YoY Change 12190.16% 4407.14%
% of Operating Profit
Other Income/Expense, Net $118.5K $38.24K $847.00
YoY Change 19234.42% 4414.88%
Pretax Income -$1.651M -$1.640M -$872.9K
YoY Change 35.93% 87.93% 1211.56%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$1.651M -$1.640M -$872.9K
YoY Change 35.93% 87.93% 1211.56%
Net Earnings / Revenue -3310.22% -204.67% -319.46%
Basic Earnings Per Share
Diluted Earnings Per Share -$0.01 -$0.01 -$6.900K
COMMON SHARES
Basic Shares Outstanding 129.0M shares 127.3M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2023 Q2 2023 Q1 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $14.60M $11.11M $11.24M
YoY Change 44.72% -1.16% 37379.33%
Cash & Equivalents $14.60M $9.153M $11.24M
Short-Term Investments $0.00 $1.961M
Other Short-Term Assets $206.5K $130.2K $167.9K
YoY Change -60.88% -22.46% 739.35%
Inventory $1.804M $1.788M
Prepaid Expenses $206.5K $130.2K $167.9K
Receivables $17.53K $26.19K
Other Receivables $0.00 $308.4K
Total Short-Term Assets $18.34M $15.04M $11.41M
YoY Change 68.87% 31.79% 22723.32%
LONG-TERM ASSETS
Property, Plant & Equipment $140.0K $140.9K $4.015K
YoY Change 1945.37% 3408.27%
Goodwill
YoY Change
Intangibles $1.047M
YoY Change
Long-Term Investments
YoY Change
Other Assets $34.31K
YoY Change
Total Long-Term Assets $1.162M $1.177M $1.051M
YoY Change 11.95% 12.0%
TOTAL ASSETS
Total Short-Term Assets $18.34M $15.04M $11.41M
Total Long-Term Assets $1.162M $1.177M $1.051M
Total Assets $19.50M $16.22M $12.46M
YoY Change 63.9% 30.12% 24824.62%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $334.2K $868.0K $144.0K
YoY Change -51.04% 502.61% -27.98%
Accrued Expenses
YoY Change
Deferred Revenue $183.1K $205.1K
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $517.3K $1.073M $910.5K
YoY Change -63.88% 17.86% 85.82%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change -100.0%
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $517.3K $1.073M $910.5K
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $517.3K $1.073M $910.5K
YoY Change -63.88% 17.86% 33.9%
SHAREHOLDERS EQUITY
Retained Earnings -$11.14M -$9.490M -$4.033M
YoY Change 112.32% 135.32%
Common Stock $13.07K $12.88K $12.67K
YoY Change 3.16% 1.69%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $18.98M $15.14M $11.55M
YoY Change
Total Liabilities & Shareholders Equity $19.50M $16.22M $12.46M
YoY Change 63.9% 30.12% 24824.62%

Cashflow Statement

Concept 2023 Q2 2023 Q1 2022 Q1
OPERATING ACTIVITIES
Net Income -$1.651M -$1.640M -$872.9K
YoY Change 35.93% 87.93% 1211.56%
Depreciation, Depletion And Amortization $15.17K $9.525K $235.00
YoY Change -9.22% 3953.19%
Cash From Operating Activities -$1.699M -$3.178M $115.9K
YoY Change 49.04% -2842.17% -2981.92%
INVESTING ACTIVITIES
Capital Expenditures $2.920K $7.303K $3.291K
YoY Change -187.95% 121.91%
Acquisitions
YoY Change
Other Investing Activities $0.00
YoY Change -100.0%
Cash From Investing Activities -$2.920K -$10.01K -$3.291K
YoY Change -99.96% 204.1%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 7.148M $8.295M $0.00
YoY Change -100.0%
NET CHANGE
Cash From Operating Activities -1.699M -$3.178M $115.9K
Cash From Investing Activities -2.920K -$10.01K -$3.291K
Cash From Financing Activities 7.148M $8.295M $0.00
Net Change In Cash 5.446M $5.106M $112.6K
YoY Change -166.88% 4434.03% 13995.12%
FREE CASH FLOW
Cash From Operating Activities -$1.699M -$3.178M $115.9K
Capital Expenditures $2.920K $7.303K $3.291K
Free Cash Flow -$1.701M -$3.186M $112.6K
YoY Change 49.74% -2928.79% -2900.1%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
97558 usd
CY2023Q1 dei Entity Central Index Key
EntityCentralIndexKey
0000933972
CY2023Q1 dei Amendment Flag
AmendmentFlag
false
CY2023Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2023Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023Q1 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
50000000 shares
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2023Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2023Q1 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
868000 usd
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
1250000 shares
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0 shares
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
0 shares
CY2023Q1 dei Document Type
DocumentType
10-Q
CY2023Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2023Q1 dei Document Period End Date
DocumentPeriodEndDate
2023-03-31
CY2023Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2023Q1 dei Entity File Number
EntityFileNumber
000-27866
CY2023Q1 dei Entity Registrant Name
EntityRegistrantName
374WATER INC.
CY2023Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
88-0271109
CY2023Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
701 W Main Street
CY2023Q1 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 410
CY2023Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Durham
CY2023Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
NC
CY2023Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
27701
CY2023Q1 dei City Area Code
CityAreaCode
919
CY2023Q1 dei Local Phone Number
LocalPhoneNumber
888-8194
CY2023Q1 dei Security12b Title
Security12bTitle
Common Stock, par value $0.0001
CY2023Q1 dei Trading Symbol
TradingSymbol
SCWO
CY2023Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2023Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2023Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2023Q1 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
129027819 shares
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
9153161 usd
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4046937 usd
CY2023Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
26188 usd
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
0 usd
CY2023Q1 us-gaap Unbilled Receivables Current
UnbilledReceivablesCurrent
1672454 usd
CY2022Q4 us-gaap Unbilled Receivables Current
UnbilledReceivablesCurrent
918164 usd
CY2023Q1 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
308374 usd
CY2022Q4 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
0 usd
CY2023Q1 us-gaap Inventory Net
InventoryNet
1788019 usd
CY2022Q4 us-gaap Inventory Net
InventoryNet
1660710 usd
CY2023Q1 us-gaap Investments
Investments
1960761 usd
CY2022Q4 us-gaap Investments
Investments
1944464 usd
CY2023Q1 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
130170 usd
CY2022Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
153455 usd
CY2023Q1 us-gaap Assets Current
AssetsCurrent
15039127 usd
CY2022Q4 us-gaap Assets Current
AssetsCurrent
8723730 usd
CY2023Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
140857 usd
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
143079 usd
CY2023Q1 us-gaap Intangible Assets Current
IntangibleAssetsCurrent
1035817 usd
CY2022Q4 us-gaap Intangible Assets Current
IntangibleAssetsCurrent
1050022 usd
CY2023Q1 us-gaap Assets Noncurrent
AssetsNoncurrent
1176674 usd
CY2022Q4 us-gaap Assets Noncurrent
AssetsNoncurrent
1193101 usd
CY2023Q1 us-gaap Assets
Assets
16215801 usd
CY2022Q4 us-gaap Assets
Assets
9916831 usd
CY2022Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
1449582 usd
CY2023Q1 us-gaap Deferred Revenue
DeferredRevenue
205109 usd
CY2022Q4 us-gaap Deferred Revenue
DeferredRevenue
200109 usd
CY2023Q1 us-gaap Other Liabilities
OtherLiabilities
0 usd
CY2022Q4 us-gaap Other Liabilities
OtherLiabilities
13528 usd
CY2022Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-872858 usd
CY2023Q1 scwo Net Loss Per Share Basic And Diluted
NetLossPerShareBasicAndDiluted
-0.01
CY2022Q1 scwo Net Loss Per Share Basic And Diluted
NetLossPerShareBasicAndDiluted
-0.01
CY2023Q1 us-gaap Liabilities Current
LiabilitiesCurrent
1073109 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1663219 usd
CY2023Q1 us-gaap Liabilities
Liabilities
1073109 usd
CY2022Q4 us-gaap Liabilities
Liabilities
1663219 usd
CY2023Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
50000000 shares
CY2023Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q1 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
128840421 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
126702545 shares
CY2023Q1 us-gaap Common Stock Value
CommonStockValue
12883 usd
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
12669 usd
CY2023Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
24619639 usd
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
16110221 usd
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-9490325 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-7849982 usd
CY2023Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
495 usd
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-19296 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
15142692 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
8253612 usd
CY2023Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
16215801 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
9916831 usd
CY2023Q1 us-gaap Revenues
Revenues
801458 usd
CY2022Q1 us-gaap Revenues
Revenues
273231 usd
CY2023Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
720146 usd
CY2022Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
247986 usd
CY2023Q1 us-gaap Gross Profit
GrossProfit
81312 usd
CY2022Q1 us-gaap Gross Profit
GrossProfit
25245 usd
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
355905 usd
CY2022Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
185653 usd
CY2023Q1 us-gaap Labor And Related Expense
LaborAndRelatedExpense
718760 usd
CY2022Q1 us-gaap Labor And Related Expense
LaborAndRelatedExpense
301235 usd
CY2023Q1 us-gaap Professional Fees
ProfessionalFees
99572 usd
CY2022Q1 us-gaap Professional Fees
ProfessionalFees
150658 usd
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
585659 usd
CY2022Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
261403 usd
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
1759896 usd
CY2022Q1 us-gaap Operating Expenses
OperatingExpenses
898950 usd
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-1678584 usd
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-873705 usd
CY2023Q1 us-gaap Interest Income Other
InterestIncomeOther
37859 usd
CY2022Q1 us-gaap Interest Income Other
InterestIncomeOther
840 usd
CY2023Q1 us-gaap Other Income
OtherIncome
382 usd
CY2022Q1 us-gaap Other Income
OtherIncome
7 usd
CY2023Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
38241 usd
CY2022Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
847 usd
CY2023Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-1640343 usd
CY2022Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-872858 usd
CY2023Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2022Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-1640343 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-872858 usd
CY2023Q1 scwo Weighted Average Number Of Shares Outstanding Basic And Diluted
WeightedAverageNumberOfSharesOutstandingBasicAndDiluted
127146695 shares
CY2022Q1 scwo Weighted Average Number Of Shares Outstanding Basic And Diluted
WeightedAverageNumberOfSharesOutstandingBasicAndDiluted
126499142 shares
CY2023Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
824 usd
CY2022Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
0 usd
CY2023Q1 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
18967 usd
CY2022Q1 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
0 usd
CY2023Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
19791 usd
CY2022Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
0 usd
CY2023Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-1620552 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
8253612 usd
CY2023Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
8294708 usd
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
214924 usd
CY2023Q1 us-gaap Foreign Currency Transaction Gain Loss Realized
ForeignCurrencyTransactionGainLossRealized
824 usd
CY2023Q1 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
18967 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
12327085 usd
CY2022Q1 scwo Conversion Of Preferred Shares To Common Shares Amount
ConversionOfPreferredSharesToCommonSharesAmount
-2 usd
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
97558 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-872858 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
11551783 usd
CY2023Q1 us-gaap Profit Loss
ProfitLoss
1640343 usd
CY2022Q1 us-gaap Profit Loss
ProfitLoss
872858 usd
CY2023Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
29105 usd
CY2022Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
16458 usd
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
214924 usd
CY2023Q1 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-824 usd
CY2022Q1 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
0 usd
CY2023Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
26188 usd
CY2022Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
0 usd
CY2023Q1 us-gaap Increase Decrease In Unbilled Receivables
IncreaseDecreaseInUnbilledReceivables
754290 usd
CY2022Q1 us-gaap Increase Decrease In Unbilled Receivables
IncreaseDecreaseInUnbilledReceivables
0 usd
CY2023Q1 us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
308374 usd
CY2022Q1 us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
0 usd
CY2023Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
127309 usd
CY2022Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
0 usd
CY2023Q1 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-23285 usd
CY2022Q1 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
50599 usd
CY2023Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-581582 usd
CY2022Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
81059 usd
CY2023Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
5000 usd
CY2022Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
763333 usd
CY2023Q1 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-13528 usd
CY2022Q1 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-20238 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3178476 usd
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
115911 usd
CY2023Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
7303 usd
CY2022Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
3291 usd
CY2023Q1 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
2705 usd
CY2022Q1 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
0 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-10008 usd
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-3291 usd
CY2023Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
8294708 usd
CY2022Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
8294708 usd
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
0 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
5106224 usd
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
112620 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
9153161 usd
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
11243795 usd
CY2023Q1 scwo Conversion Of Preferred Stock To Common Stock
ConversionOfPreferredStockToCommonStock
0 usd
CY2022Q1 scwo Conversion Of Preferred Stock To Common Stock
ConversionOfPreferredStockToCommonStock
133 usd
CY2023Q1 us-gaap Cash
Cash
2696107 usd
CY2022Q4 us-gaap Cash
Cash
1182412 usd
CY2023Q1 scwo Investments Adjusted Cost
InvestmentsAdjustedCost
11113922 usd
CY2023Q1 scwo Unrealized Loss
UnrealizedLoss
8049 usd
CY2023Q1 us-gaap Investments Fair Value Disclosure
InvestmentsFairValueDisclosure
11105873 usd
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
9153161 usd
CY2023Q1 scwo Marketables Securities Current
MarketablesSecuritiesCurrent
1952712 usd
CY2023Q1 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
0 usd
CY2022Q4 scwo Investments Adjusted Cost
InvestmentsAdjustedCost
6010369 usd
CY2022Q4 scwo Unrealized Loss
UnrealizedLoss
18968 usd
CY2022Q4 us-gaap Investments Fair Value Disclosure
InvestmentsFairValueDisclosure
5991401 usd
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4046937 usd
CY2022Q4 scwo Marketables Securities Current
MarketablesSecuritiesCurrent
1944464 usd
CY2022Q4 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
0 usd
CY2023Q1 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
191 usd
CY2022Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
0 usd
CY2023Q1 scwo Accounts And Receivable Allowance For Credit Loss
AccountsAndReceivableAllowanceForCreditLoss
0 usd
CY2022Q1 scwo Accounts And Receivable Allowance For Credit Loss
AccountsAndReceivableAllowanceForCreditLoss
0 usd
CY2023Q1 scwo Accounts Receivable Allowance For Credit Losses Current Period Provision
AccountsReceivableAllowanceForCreditLossesCurrentPeriodProvision
191 usd
CY2022Q1 scwo Accounts Receivable Allowance For Credit Losses Current Period Provision
AccountsReceivableAllowanceForCreditLossesCurrentPeriodProvision
0 usd
CY2023Q1 us-gaap Proceeds Accounts Receivable Previously Written Off Recovery
ProceedsAccountsReceivablePreviouslyWrittenOffRecovery
0 usd
CY2022Q1 us-gaap Proceeds Accounts Receivable Previously Written Off Recovery
ProceedsAccountsReceivablePreviouslyWrittenOffRecovery
0 usd
CY2023Q1 scwo Accounts And Financing Receivables Allowance For Credit Loss
AccountsAndFinancingReceivablesAllowanceForCreditLoss
191 usd
CY2022Q1 scwo Accounts And Financing Receivables Allowance For Credit Loss
AccountsAndFinancingReceivablesAllowanceForCreditLoss
0 usd
CY2023Q1 us-gaap Depreciation
Depreciation
9525 usd
CY2022Q1 us-gaap Depreciation
Depreciation
235 usd
CY2023Q1 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Financial instruments that potentially subject the Company to credit risk consist of cash and cash equivalents, and marketable securities. Deposits with financial institutions are insured, up to certain limits, by the Federal Deposit Insurance Corporation (“FDIC”). The Company’s cash deposits often exceed the FDIC insurance limit; however, all deposits are maintained with high credit quality institutions and the Company has not experienced any losses in such accounts. The financial condition of financial institutions is periodically reassessed, and the Company believes the risk of any loss is minimal. The Company believes the risk of any loss on cash due to credit risk is minimal. Furthermore, we perform ongoing credit evaluations of our customers and generally do not require collateral.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Significant customers and suppliers are those that account for greater than 10% of the Company’s revenues and purchases.  Our customer revenue for one customer made up over 90% of revenue for the period ended March 31, 2023 and year ended December 31, 2022. In 2023 and 2022, the Company purchased a substantial portion of manufacturing services from one third party vendor, Merrell Bros Fabrication, LLC. </p>
CY2023Q1 scwo Billings Deferred Unearned Revenue
BillingsDeferredUnearnedRevenue
5000 usd
CY2022 scwo Billings Deferred Unearned Revenue
BillingsDeferredUnearnedRevenue
1467189 usd
CY2023Q1 scwo Revenues From Sales
RevenuesFromSales
793458 usd
CY2023Q1 scwo Revenues From Sale Of Treatability Services
RevenuesFromSaleOfTreatabilityServices
8000 usd
CY2022 scwo Revenues From Sales
RevenuesFromSales
2952020 usd
CY2022 scwo Revenues From Sale Of Treatability Services
RevenuesFromSaleOfTreatabilityServices
63501 usd
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
355905 usd
CY2022Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
185653 usd
CY2023Q1 scwo Recognition Of Prior Unearned Revenue
RecognitionOfPriorUnearnedRevenue
0 usd
CY2022 scwo Recognition Of Prior Unearned Revenue
RecognitionOfPriorUnearnedRevenue
-1267080 usd
CY2023Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of income and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates in the accompanying financial statements include the fair value of equity-based compensation, revenue, fair value of intangible assets, useful lives of intangible assets, capital raise transactions, and valuation allowance against deferred tax assets.</p>
CY2023Q1 us-gaap Capital
Capital
13966018 usd
CY2022Q4 us-gaap Capital
Capital
7060511 usd
CY2023Q1 scwo Net Income Loss1
NetIncomeLoss1
1640343 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Continuing Operations
NetCashProvidedByUsedInContinuingOperations
3178476 usd
CY2023Q1 us-gaap Inventory Raw Materials
InventoryRawMaterials
533925 usd
CY2022Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
755218 usd
CY2023Q1 us-gaap Inventory Work In Process
InventoryWorkInProcess
1254094 usd
CY2022Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
905492 usd
CY2023Q1 us-gaap Inventory Net
InventoryNet
1788019 usd
CY2022Q4 us-gaap Inventory Net
InventoryNet
1660710 usd
CY2023Q1 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
205109 usd
CY2022Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
200109 usd
CY2022Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
1050022 usd
CY2023Q1 us-gaap Finitelived Intangible Assets Acquired1
FinitelivedIntangibleAssetsAcquired1
2705 usd
CY2022 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
16910 usd
CY2023Q1 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
1035817 usd
CY2021Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
1062856 usd
CY2022 us-gaap Finitelived Intangible Assets Acquired1
FinitelivedIntangibleAssetsAcquired1
52292 usd
CY2023Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
65126 usd
CY2022Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
1050022 usd
CY2023Q1 scwo Amortization Expense
AmortizationExpense
16910 usd
CY2022 scwo Amortization Expense
AmortizationExpense
16458 usd
CY2023Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
50827 usd
CY2023Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
67769 usd
CY2023Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
67769 usd
CY2023Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
67769 usd
CY2023Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
67769 usd
CY2023Q1 us-gaap Finite Lived Intangible Assets Amortization Expense After Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive
713914 usd
CY2023Q1 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
1035817 usd
CY2023Q1 us-gaap Revenues
Revenues
801458 usd
CY2023Q1 scwo Revenue Percentage
RevenuePercentage
1 pure
CY2022Q1 us-gaap Revenues
Revenues
273231 usd
CY2022Q1 scwo Revenue Percentage
RevenuePercentage
1 pure
CY2022Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
200109 usd
CY2021Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
0 usd
CY2022Q4 us-gaap Accounts Receivable Net
AccountsReceivableNet
918164 usd
CY2021Q4 us-gaap Accounts Receivable Net
AccountsReceivableNet
0 usd
CY2023Q1 scwo Services Performed But Unbilled
ServicesPerformedButUnbilled
793458 usd
CY2022 scwo Services Performed But Unbilled
ServicesPerformedButUnbilled
918164 usd
CY2023Q1 scwo Services Billed
ServicesBilled
-39168 usd
CY2022 scwo Services Billed
ServicesBilled
0 usd
CY2023Q1 us-gaap Accounts Receivable Net
AccountsReceivableNet
1672454 usd
CY2022Q4 us-gaap Accounts Receivable Net
AccountsReceivableNet
918164 usd
CY2023Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
50000000 shares
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2023Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
128840421 shares
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
214924 usd
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
97558 usd
CY2023Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
2213723 usd
CY2023Q1 scwo Unrecognized Compensation Vesting Period
UnrecognizedCompensationVestingPeriod
four years
CY2023Q1 scwo Warrants Outstanding Series One Shares
WarrantsOutstandingSeriesOneShares
1250000 shares
CY2023Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
2.50
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Vested
SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested
2775000 usd
CY2023Q1 scwo Price Of Market
PriceOfMarket
4.72
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
1250000 shares
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
1250000 shares
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
2.50
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
450000 usd
CY2023Q1 scwo Weighted Average Remaining Contractual Life Years Beginning Balance
WeightedAverageRemainingContractualLifeYearsBeginningBalance
P1Y11M15D
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0
CY2023Q1 scwo Aggregate Intrinsic Value Issued
AggregateIntrinsicValueIssued
0 usd
CY2023Q1 scwo Weighted Average Exercise Price Exercised
WeightedAverageExercisePriceExercised
0
CY2023Q1 scwo Aggregate Intrinsic Value Exercised
AggregateIntrinsicValueExercised
0 usd
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
1250000 shares
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
2.50
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
2775000 usd
CY2023Q1 scwo Weighted Average Remaining Contractual Life Years Ending Balance
WeightedAverageRemainingContractualLifeYearsEndingBalance
P1Y8M19D
CY2023Q1 scwo Stock In Excess Percentage Of Outstanding Share
StockInExcessPercentageOfOutstandingShare
0.05 pure
CY2023Q1 us-gaap Related Party Costs
RelatedPartyCosts
446081 usd
CY2023Q1 us-gaap Related Party Transaction Expenses From Transactions With Related Party
RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
432582 usd

Files In Submission

Name View Source Status
scwo-20230331_cal.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
scwo-20230331_def.xml Edgar Link unprocessable
0001654954-23-005904-index-headers.html Edgar Link pending
0001654954-23-005904-index.html Edgar Link pending
0001654954-23-005904.txt Edgar Link pending
0001654954-23-005904-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
scwo-20230331.xsd Edgar Link pending
scwo_10q.htm Edgar Link pending
scwo_ex311.htm Edgar Link pending
scwo_ex312.htm Edgar Link pending
scwo_ex321.htm Edgar Link pending
scwo_ex322.htm Edgar Link pending
Show.js Edgar Link pending
scwo-20230331_lab.xml Edgar Link unprocessable
scwo-20230331_pre.xml Edgar Link unprocessable
scwo_10q_htm.xml Edgar Link completed